In 2017, inotuzumab ozogamicin (INO), a humanized anti-CD22 mAb linked to the cytotoxic antibiotic calicheamicin, was approved as a monotherapy for the treatment of CD22-positive B-ALL [114]. This evidence concerns the gene CD22 and acute lymphoblastic leukemia.